Application of PLpro protein inhibitor in medicines for treating or preventing novel coronavirus infection

A technology for protein inhibitors and coronaviruses, which can be used in antiviral agents, pharmaceutical formulations, active ingredients of heterocyclic compounds, etc., and can solve problems such as high risk of side effects

Inactive Publication Date: 2020-12-04
PEKING UNIV SHENZHEN GRADUATE SCHOOL +1
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Common side effects include bone marrow suppression, liver damage, and oral inflammation, and people with thiopurine methyltransferase deficiency have a higher risk of side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PLpro protein inhibitor in medicines for treating or preventing novel coronavirus infection
  • Application of PLpro protein inhibitor in medicines for treating or preventing novel coronavirus infection
  • Application of PLpro protein inhibitor in medicines for treating or preventing novel coronavirus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Example 1: Induced expression and purification of PLpro protein

[0066] Transform the PLpro prokaryotic expression plasmid (see SEQ ID NO.1 for the amino acid sequence of the expressed PLpro protein) into BL21 (DE3) Escherichia coli competent cells, and grow in LB medium at 37°C until the OD600 is 0.6-0.8 Time. Add 0.5mM IPTG to induce protein expression and add 1mM zinc chloride (ZnCl 2 ), and then grow E. coli overnight at 18°C. After collection by centrifugation, resuspend the cell pellet with 50mM Tris-HCl, 150mM NaCl, 10mM Imidazole, 2mM DTT, and buffer solution of pH=8.5, break it by ultrasonic, and centrifuge at 18000rpm to get the supernatant. Purified with His-TRAPTM chromatographic column, finally washed out with buffer (50mM Tris-HCl, 150mM NaCl, 250mM midazole, 1mM DTT, pH 7.4), further purified on gel chromatographic column (Superdex 20016 / 60, GE), The SEC buffer is 20 mM Tris-HCl, 100 mM NaCl, 1 mMDTT, and its pH is 7.4. Purified PLpro protein was con...

Embodiment 2

[0067] Embodiment 2: In vitro experiments measure the activity (IC50) of thioguanine (6-TG) inhibiting PLpro protein

[0068] The reaction system was 50 μL, in which the concentration of PLpro was 30 nM, the concentration of the substrate Ub-AMC (Boston Biochem) was 250 nM, the reaction buffer was 50 mM Hepes (pH=7.5), 0.01% Trixton X-100, 0.1 mg / ml BSA and 2 mMDTT . Add gradient concentration (100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78μM) of inhibitor thioguanine (6-TG), and then use a microplate reader to measure the fluorescence emission intensity (excitation: 340nm; emission: 430nm ), the activity (IC50) of thioguanine (6-TG) inhibiting PLpro enzyme was calculated according to the fluorescence intensity, and the inhibition curve was fitted using GraphPad Prism. For fitting results see figure 2 .

Embodiment 3

[0069] Embodiment 3: P3 laboratory tests the inhibitory activity of thioguanine (6-TG) to new coronavirus

[0070] (1) Compound cytotoxicity test:

[0071] Will 1×10 4 The Vero cells (source: VERO cells are from the Cell Resource Center of the Shanghai Institute of Biological Sciences, Chinese Academy of Sciences) were inoculated in 96-well plates, and three replicate wells were set up, grown at 37 degrees for 20-24 hours, the medium was removed, and 100 μL containing different concentration Compounds (100, 50, 25, 12.5, 6.25, 3.125, 1.56, 0 μM) were grown in new media for 72 hours, using DMSO as a control, using MTS / CCK8 reagents (the above reagents were purchased from: Beijing Suo Lai Bao Technology Co., Ltd., Product No. CK04-500T), measure the cell viability, and calculate the cytotoxicity (CC50) of the compound.

[0072] (2) Compound inhibitory virus activity test:

[0073] Will 1×10 4 Vero cells were seeded in a 96-well plate, and three replicate wells were set up, g...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of a PLpro protein inhibitor in preparation of medicines for treating or preventing diseases related to novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, and provides a pharmaceutical composition containing the PLpro protein inhibitor and used for preparing medicines for treating or preventing diseases related to novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

Description

technical field [0001] The present invention relates to the use of PLpro protein inhibitors in the preparation of medicines for the treatment or prevention of new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-related diseases, and provides PLpro inhibitors for the preparation of new types of drugs for the treatment or prevention of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A pharmaceutical composition for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-related diseases. Background technique [0002] Coronaviruses are a class of positive-sense RNA viruses that pose significant health risks. Coronaviruses are genetically divided into four major virus genera: Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus. The first two genera mainly infect mammals, while the latter two mainly infect birds. Before the discovery of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/522A61P31/14
CPCA61P31/14A61K31/7076A61P11/00
Inventor 黄昊张国良汤金乐刘淑燕付子阳刘明
Owner PEKING UNIV SHENZHEN GRADUATE SCHOOL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap